SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Claris Lifesciences soars on receiving PAS for Furosemide Injection in US

Claris Lifesciences Ltd. | Trading | Miscellaneous | BSE: 533288 | NSE:

12 Aug 2015 Evaluate

Claris Lifesciences is currently trading at Rs. 229.80, up by 9.50 points or 4.31% from its previous closing of Rs. 220.30 on the BSE.

The scrip opened at Rs. 219.90 and has touched a high and low of Rs. 232.00 and Rs. 214.60 respectively. So far 1,32,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 358.00 on 13-Apr-2015 and a 52 week low of Rs. 163.10 on 22-Oct-2014.

Last one week high and low of the scrip stood at Rs. 234.90 and Rs. 214.60 respectively. The current market cap of the company is Rs. 1,467.00 crore.

The promoters holding in the company stood at 60.99% while Institutions and Non-Institutions held 17.82% and 21.18% respectively.

Claris Lifesciences has received the Prior Approval Supplement (PAS) for Furosemide Injection in the United States of America (US). The company had received the original approval for this ANDA in January 2014 and was selling the products in the US in 2014. But, since January 2015, the company has been facing supply issues from its raw material supplier and has not been able to supply its product to the US.

The company had filed a PAS application to append an additional supplier to the ANDA, this process was done for redundancy and to ensure a consistent supply of the API for its finished formulation sold in the US. With this approval, alterative vendor has been appended to the ANDA this will allow the company to recommence its supplies to the US. The product had been facing supply issues in USA during the past year on various occasions and has also featured in the USFDA shortage list since June 2012.

Claris is also one of the few injectables companies in India to have its own front end in the US, the company markets its products through its wholly owned subsidiary Claris Lifesciences Inc. The company has 13 ANDAs approved in its name across 8 molecules. The company has a under registration pipeline of 24 ANDAs across 21 molecules having an estimated addressable market size of $2.2 billion.

Claris Lifesciences Share Price

Not Listed

View Price Chart

Peers

Company Name	CMP
Redington	228.15
Adani Enterprises	2239.05
Amrapali Industries	17.36
Rashi Peripheral	474.40
PDS	293.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

PROPRIETARY FRAMEWORK

Portfolio
Architecture >
Stock Picking.

Stop managing a collection of "tips." Access the ABC Framework to build a portfolio that survives cycles and compounds wealth.

Core for Stability

Booster for Alpha

Amplifier for Exponential Wealth

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Access Sapphire ABC Strategy →

Limited Capacity for New Fiduciary Partners

Claris Lifesciences soars on receiving PAS for Furosemide Injection in US

MoneyWorks4Me Premium

Follow us at

MoneyWorks4Me

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.